Executive Management

Keith Valentine was appointed Director, President and CEO following the merger with SeaSpine. Prior to this, Mr. Valentine served as the CEO and President of SeaSpine since 2015. Before joining SeaSpine, he was President and Chief Operating Officer of NuVasive Inc. from 2007 to 2015 and as President of NuVasive from 2004 to 2007. While at NuVasive, Mr. Valentine served in various senior executive roles of increasing responsibility in marketing, development, and operations. Previously, he served as Vice President of Marketing at ORATEC Interventions Inc., a medical device company acquired by Smith & Nephew PLC, and spent eight years in various roles with Medtronic Sofamor Danek, including Vice President of Marketing for the Rods Division and Group Director for the BMP Biologics program, the Interbody Sales Development Effort, and International Sales and Marketing. Mr. Valentine currently serves on the Board of Directors of SI-BONE, Inc., a publicly traded medical device company focused on the treatment of musculoskeletal disorders of the sacro-pelvic anatomy and serves as Chair of its nominating and governance committee. Mr. Valentine received a B.B.A. in Management and Biomedical Sciences from Western Michigan University.

Suzanne Armstrong currently serves as Chief Human Resources Officer. Ms. Armstrong joined Orthofix in 2007, became Vice President of Human Resources in 2017, and was then promoted to Senior Vice President of Human Resources. She is responsible for all aspects of the Company’s overall talent management strategy, including talent acquisition, compensation, benefits, and organizational learning and development. Prior to joining Orthofix, Ms. Armstrong spent more than 15 years in a variety of human resources roles within the life sciences and technologies industries. She holds a Bachelor of Science degree in Public Affairs from Indiana University.

John Bostjancic was appointed Chief Financial Officer following the merger. Mr. Bostjancic previously served as Chief Financial Officer of SeaSpine since 2015, and in 2022, Mr. Bostjancic was appointed to his expanded role at SeaSpine of Chief Operating and Financial Officer. Prior to this, he served as Treasurer and Senior Vice President at SeaSpine. Previously Mr. Bostjancic served as acting Chief Financial Officer of the SeaSpine business within Integra Life Sciences Holdings Corporation since 2014, and prior to that, he was Senior Vice President of Global Supply Chain at Integra from 2012 to 2014. His responsibilities included global planning, kitting, distribution, logistics, and customer service in the role, and he led the project team implementing the U.S. Food and Drug Administration’s “unique device identifier” rule in 2014. From 2008 until 2012, Mr. Bostjancic was Senior Vice President of Financial Planning and Analysis at Integra. Since joining Integra in 1999, he held roles of increasing responsibility in the finance organization, including corporate controller from 2003 through 2006. Before joining Integra, from 1998 through 1999, Mr. Bostjancic was a manager in the accounting standards team at Merck & Co., Inc., a publicly traded health care company. Prior to that, he worked in the business assurance organization at PricewaterhouseCoopers from 1993 through 1998. He received his B.S. in Accounting from the College of New Jersey.

Before becoming Senior Vice President, Global Operations, Roberto Donadello joined Orthofix in 2007 as Operations Director and was promoted to Vice President of International Operations in 2009. In 2010, Mr. Donadello assumed additional responsibilities for the International Quality and Regulatory Affairs teams. In conjunction with this, he also served as the General Manager of the Orthofix Orthosonics business. In 2020, Mr. Donadello was promoted to the position of Senior Vice President, Global Operations leading worldwide operations for the Orthofix Spine and Orthopedics businesses. Prior to joining Orthofix, he served as Operations Director for SIAC SpA, an Italian manufacturing group. Mr. Donadello holds an Aeronautical Engineering degree from the Polytechnic University of Milan.

Kimberley Elting currently serves as the President of Global Orthopedics. Ms. Elting joined the Orthofix Leadership team as Chief Legal Officer in 2016, was named Chief Legal and Administrative Officer in 2017, and Chief Legal and Development Officer in 2020. She was appointed President of Global Orthopedics in April 2022. A seasoned executive, Ms. Elting has a strong background in the medical device industry. Before coming to Orthofix, she served as General Counsel and Vice President of Corporate Affairs at TriVascular Technologies, Inc. In this role, she led the legal, compliance, human resources (HR), and government affairs functions for the company. Prior to this, Ms. Elting served in various roles of increasing responsibility with St. Jude Medical including General Counsel and Vice President of HR and Health Policy for the Neuromodulation Division. Ms. Elting previously was a partner at the Jones Day law firm. A graduate of Ithaca College, Ms. Elting earned her Law Degree from the University of Denver and an LL.M. in Health Law from Loyola University Chicago.

Ehab Esmail joined Orthofix in 2019 and serves as the Senior Vice President of Global Quality, Regulatory and Clinical Affairs. A seasoned executive with more than 26 years of diverse experience in the orthopedic medical device and biologic industries, Mr. Esmail most recently served as the Vice President of Global Regulatory Affairs and Regulatory Compliance for DJO where he supported all business units covering orthopedic surgical implants, bracing and supports, foot care, consumer products and recovery science. Prior to DJO, he held leadership positions of increasing responsibility with Zimmer Biomet, Biolase, Wright Medical and Smith & Nephew. Mr. Esmail earned his Bachelor of Science in Mechanical Engineering from the University of Memphis. He is active in many professional organizations including serving as the past President and Board Member of the Orthopedic Surgical Manufacturers Association (OSMA).

Kevin Kenny currently serves as President of Global Spine. Mr. Kenny became President of the Global Spine business at Orthofix in 2019. Before joining Orthofix, Mr. Kenny previously served as Vice President of U.S. Sales for Medtronic Spine and Biologics where he oversaw all sales functions for approximately 1,500 direct and non-direct sales personnel. During his nine-year tenure with Medtronic, Mr. Kenny held a variety of sales roles, each with increasing areas of responsibility. More recently he served as the Chief Operating Officer for Cardiovascular Systems Incorporated where he drove business strategies focused on developing and commercializing new products worldwide. Earlier in his career, Mr. Kenny served as Vice President of Sales for Bausch and Lomb, and also held various sales leadership roles with B. Braun/McGaw, a worldwide manufacturer and distributor of medical devices. Mr. Kenny serves on the board of directors for the Medical Device Manufacturers Association. He earned his B.S. in Business Administration from California State University in Sacramento, CA.

Patrick Keran was appointed Chief Legal Officer following the merger. Mr. Keran previously served as General Counsel of SeaSpine since 2015, secretary since 2016, and a Senior Vice President since 2020. Prior to joining SeaSpine, Mr. Keran provided strategic and business advisory services to a variety of life sciences companies, including acting as Chief Legal Officer to NAIA Pharmaceuticals, Inc., a privately held international drug development company. From 2010 to 2015, he served as President and Chief Operating Officer of Mast Therapeutics, Inc., a publicly held clinical stage biopharmaceutical company, and from 2006 to 2010, Mr. Keran served as its General Counsel. He also served as Mast’s secretary from 2006 to 2015 and served as its Principal Financial Officer from 2009 to 2013. Previously, from 2004 to 2006, Mr. Keran was associate General Counsel at Ionis Pharmaceuticals, Inc. (formerly known as Isis Pharmaceuticals, Inc.), a publicly held drug discovery and development company. From 1999 to 2004, Mr. Keran practiced corporate law at the law firms of Heller Ehrman LLP and Brobeck Phleger & Harrison LLP, specializing in public and private financings, licensing arrangements, mergers and acquisitions, and corporate governance matters. He is licensed to practice law in the State of California. Mr. Keran received a B.A. from the University of California at San Diego and a J.D. from the University of California at Berkeley, Boalt Hall School of Law.

Tyler Lipschultz was appointed President, Global Biologics following the merger. Mr. Lipschultz previously served as Senior Vice President, Orthobiologics and Business Development at SeaSpine since 2018 and served as Vice President, Orthobiologics and Business Development at SeaSpine from 2015 to 2018. Before joining SeaSpine, from 2008 to 2015, Mr. Lipschultz held positions of increasing responsibility at NuVasive, Inc., a publicly traded medical device company, most recently serving as its Executive Vice President, Global Operations and, prior to that, Executive Vice President, Biologics. Prior to joining NuVasive, he was a Director at ProtoStar, a medical device incubator that formed Annulex, CVRx, and VERTx, which Mr. Lipschultz cofounded. In 2002, VERTx merged with Spine Wave, where he subsequently served in a variety of roles, including Executive Vice President and General Manager of the mechanical business. Prior to ProtoStar, Mr. Lipschultz held the position of Equity Research Analyst at Piper Jaffray and served in various marketing/product management roles at Stryker, Smith & Nephew, and DePuy. He received a B.A. in Economics and Business Administration from Kalamazoo College and an M.B.A. from the executive program at Krannert School of Management at Purdue University.

Dr. Beau Standish was appointed President, Global Enabling Technologies following the merger. Dr. Standish joined SeaSpine in 2021 as the President of Enabling Technologies. Before joining SeaSpine, Dr. Standish served as a cofounder and Chief Executive Officer of 7D Surgical from 2014 to 2021; prior to 7D, he was an assistant professor in the Department of Electrical and Computer Engineering at Ryerson University in Toronto, Canada. Dr. Standish is an author on 50+ patents and leads the research, development, and commercialization of SeaSpine’s machine-vision image guidance suite of products. Dr. Standish leverages his 16+ years of experience in the medical imaging space to bring products from the idea phase through to full commercialization. He achieved his Bachelor of Engineering from McMaster University in Hamilton, Canada, and holds a Ph.D. in Medical Biophysics from the University of Toronto, where he was a Terry Fox Scholar of the National Cancer Institute of Canada.

Frank Vizesi, Ph. D., was appointed Chief Scientific Officer following the merger. Dr. Vizesi previously served as Chief Scientific Officer at SeaSpine, where he joined in September 2015 and previously held the role of Vice President, Orthobiologics Research & Development, and Clinical Affairs. Dr. Vizesi was responsible for research and product development of the orthobiologics portfolio, as well as clinical and preclinical research for all of SeaSpine. He has dedicated his career to the intersection of engineering and biology in spine and orthopaedics and developed and launched market-leading products supported by scientific evidence. Prior to SeaSpine, Dr. Vizesi spent eight years at NuVasive and played a pivotal role in growing its biologics franchise to more than $100 million annual revenue. Dr. Vizesi completed his Ph. D. in Biomedical Engineering, M.E. in Biomedical Engineering, and B.E. in Biomedical Engineering from the University of New South Wales in Sydney, Australia.